Third Person Shooter Do I regret yeeting my blueprints and loot-filled stash into Arc Raiders Expedition? No, it actually made the game fun again Action Huh, Arc Raiders' maps are heavily based on ...

Third Person Shooters Arc Raiders players make a plea to Embark: don't let PvP in trios poison your solo "aggression-based" matchmaking Third Person Shooters While playing Arc Raiders, Embark leads ...

Shane Limbaugh (He/Him) is a Contributor from the US. While he hasn't been writing about games for very long he has certainly been playing them. His degree in Game Design and Criticism let him better ...

FuRyu has announced Beyblade X: EVOBATTLE, a follow-up to 2024’s Beyblade X: XONE, for Switch and PC (Steam). It will launch on November 13. In Japan, the physical edition for Switch will be priced at ...

Forbes contributors publish independent expert analyses and insights. Ollie Barder covers Japanese pop-culture and gaming from Tokyo. Last year’s tournament was more of a national one, and it pitted ...

Inspired by the anime and toys, Beyblade X-Battles has fast-paced, customizable spinning tops with special Xtreme Dash mechanics, allowing you to boost your Beyblade's speed, perform unanticipated ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Kwan Wei Kevin Tan Every time Kwan Wei Kevin Tan publishes a story, you’ll get an alert ...

For over two decades, Beyblade has been the brand that effortlessly turned school lunch tables into high-adrenaline stadiums and friends into sworn rivals. But with the launch of Beyblade X, the ...

NEW YORK--(BUSINESS WIRE)--Today, Blueprint Finance, a multi-chain DeFi infrastructure company and the core developer of both the Ethereum-based Concrete and Solana-based Glow Finance, announced it ...

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio. Sanofi will pay $129 ...

In late April, when Sanofi revealed that it was selling a controlling stake in its consumer health business Opella for 10 billion euros ($11.4 billion), chief financial officer Francois Roger said ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...